Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Medical School

The Ohio State University School of Medicine

2006, Columbus, OH

Internship

General Surgery

Indiana University School of Medicine

2007, Indianapolis, IN

Residency

Surgery

Indiana University School of Medicine

2012, Indianapolis, IN

Fellowship

Pediatric General Surgery

Boston Children's Hospital

2015, Boston, MA

Certifications

  • American Board of Surgery (General)
  • American Board of Surgery (Pediatric Surgery)

Professional History

Dr. Weil's clinical interests are pediatric surgical oncology, inflammatory bowel disease, pediatric general surgery, and minimally invasive surgery.

Publications

  1. Prevalence, Characteristics, and Management of Pancreatic Tumors Among Children With Tuberous Sclerosis Complex. J Pediatr Surg. 2025 Apr 24; 60(7):162339. View Abstract

  2. Prevalence of carotid ultrasound screening in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer. 2025 Jan 01; 131(1):e35591. View Abstract

  3. Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group report. J Natl Cancer Inst. 2024 Oct 01; 116(10):1664-1674. View Abstract

  4. Current surgical approach: Extracranial malignant germ cell tumors. Pediatr Blood Cancer. 2025 Apr; 72 Suppl 2:e31217. View Abstract

  5. Long-term outcomes among survivors of childhood osteosarcoma: A report from the Childhood Cancer Survivor Study (CCSS). Pediatr Blood Cancer. 2024 Oct; 71(10):e31189. View Abstract

  6. Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2024 Jun 07; 116(6):885-894. View Abstract

  7. Biallelic EPCAM deletions induce tissue-specific DNA repair deficiency and cancer predisposition. NPJ Precis Oncol. 2024 Mar 11; 8(1):69. View Abstract

  8. Critical elements of pediatrics sacrococcygeal germ cell tumor surgery. Semin Pediatr Surg. 2023 Oct; 32(5):151344. View Abstract

  9. Critical elements in the operative management of pediatric malignant ovarian germ cell tumors. Semin Pediatr Surg. 2023 Oct; 32(5):151342. View Abstract

  10. Characterizing Lymphovascular Invasion in Pediatric and Adolescent Malignant Ovarian Nongerminomatous Germ Cell Tumors: A Report from the Children's Oncology Group. J Pediatr Surg. 2023 Dec; 58(12):2399-2404. View Abstract

  11. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract

  12. Lymphatic Embolization for the Management of Post-operative Chyle Leaks Following Solid Tumor Resection in Pediatric Patients. J Pediatr Surg. 2023 Nov; 58(11):2141-2148. View Abstract

  13. Efficacy and Safety of Tacrolimus or Infliximab Therapy in Children and Young Adults With Acute Severe Colitis. J Pediatr Gastroenterol Nutr. 2023 08 01; 77(2):222-227. View Abstract

  14. Cumulative burden of late, major surgical intervention in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS) cohort. Lancet Oncol. 2023 06; 24(6):691-700. View Abstract

  15. Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer. J Clin Oncol. 2023 04 20; 41(12):2258-2268. View Abstract

  16. Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2023 05 10; 41(14):2638-2650. View Abstract

  17. Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2023 03 10; 41(8):1565-1576. View Abstract

  18. What Are Risk Factors for and Outcomes of Late Amputation After Treatment for Lower Extremity Sarcoma: A Childhood Cancer Survivor Study Report. Clin Orthop Relat Res. 2023 03 01; 481(3):526-538. View Abstract

  19. Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2022 09; 69(9):e29616. View Abstract

  20. Complications associated with totally implantable access ports in children less than 1 year of age. J Pediatr Surg. 2022 Oct; 57(10):463-468. View Abstract

  21. Belzutifan, a Potent HIF2a Inhibitor, in the Pacak-Zhuang Syndrome. N Engl J Med. 2021 11 25; 385(22):2059-2065. View Abstract

  22. Interdisciplinary Management of Malignant Ovarian Tumors in the Pediatric and Adolescent Age Group. J Pediatr Adolesc Gynecol. 2022 Jun; 35(3):260-264. View Abstract

  23. Where Did the Blood Go?: A Meckel's Diverticulum Bleed Without Hematochezia or Melena. JPGN Rep. 2021 Nov; 2(4):e119. View Abstract

  24. Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Eur J Cancer. 2021 09; 155:216-226. View Abstract

  25. Sex-Specific Associations Between Chemotherapy, Chronic Conditions, and Neurocognitive Impairment in Acute Lymphoblastic Leukemia Survivors: A Report From the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2021 05 04; 113(5):588-596. View Abstract

  26. Safety of Surgical Fertility Preservation Procedures in Children Prior to Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2021 08; 27(8):696.e1-696.e4. View Abstract

  27. Neonatal Malignant Disorders: Germ Cell Tumors. Clin Perinatol. 2021 03; 48(1):147-165. View Abstract

  28. Management of Germ Cell Tumors in Pediatric Patients. Surg Oncol Clin N Am. 2021 04; 30(2):325-338. View Abstract

  29. Epidemiology of abdominal wall and groin hernia repairs in children. Pediatr Surg Int. 2021 May; 37(5):587-595. View Abstract

  30. Opioid Prescription Patterns for Children Following Laparoscopic Appendectomy. Ann Surg. 2020 12; 272(6):1149-1157. View Abstract

  31. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View Abstract

  32. Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Eur J Cancer. 2020 07; 133:4-13. View Abstract

  33. Comparison of Military Health System Data Repository and American College of Surgeons National Surgical Quality Improvement Program-Pediatric. BMC Pediatr. 2019 11 08; 19(1):419. View Abstract

  34. Late-onset anorectal disease and psychosocial impact in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer. 2019 11 01; 125(21):3873-3881. View Abstract

  35. Therapeutic Impact and Complications Associated with Surgical Lung Biopsy after Allogeneic Hematopoietic Stem Cell Transplantation in Children. Biol Blood Marrow Transplant. 2019 11; 25(11):2181-2185. View Abstract

  36. Multicenter pre-operative assessment of pediatric ovarian malignancy. J Pediatr Surg. 2019 Sep; 54(9):1921-1925. View Abstract

  37. Fertility and hormone preservation and restoration for female children and adolescents receiving gonadotoxic cancer treatments: A systematic review. J Pediatr Surg. 2019 Nov; 54(11):2200-2209. View Abstract

  38. Update on Wilms tumor. J Pediatr Surg. 2019 Mar; 54(3):390-397. View Abstract

  39. Update on neuroblastoma. J Pediatr Surg. 2019 Mar; 54(3):383-389. View Abstract

  40. Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2018 Sep 14; JCO2018784595. View Abstract

  41. Incidence and risk factors for sepsis after childhood splenectomy. J Pediatr Surg. 2019 Jul; 54(7):1445-1448. View Abstract

  42. New Agents, Emerging Late Effects, and the Development of Precision Survivorship. J Clin Oncol. 2018 07 20; 36(21):2231-2240. View Abstract

  43. Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2018 06 01; 36(16):1571-1578. View Abstract

  44. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560. View Abstract

  45. Hernia recurrence following inguinal hernia repair in children. J Pediatr Surg. 2018 Nov; 53(11):2214-2218. View Abstract

  46. Primary laparoscopic gastrojejunostomy tubes as a feeding modality in the pediatric population. J Pediatr Surg. 2017 Sep; 52(9):1421-1425. View Abstract

  47. The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review. Pediatr Surg Int. 2017 Jun; 33(6):683-694. View Abstract

  48. Autoamputation of the Appendix Presenting as a Calcified Abdominal Mass Following Necrotizing Enterocolitis. Pediatr Dev Pathol. 2017 Jul-Aug; 20(4):335-339. View Abstract

  49. Safety and cost-effectiveness of port removal outside of the operating room among pediatric patients. J Pediatr Surg. 2016 Nov; 51(11):1891-1895. View Abstract

  50. Autoamputation of the appendix presenting as a calcified abdominal mass following necrotizing enterocolitis. Pediatr Dev Pathol. 2016 Mar 28. View Abstract

  51. Commentary on "Simultaneous Resection of High-risk Liver Tumors and Pulmonary Metastases in Children". Ann Surg. 2015 Jul; 262(1):e4. View Abstract

  52. Prospective determination of percutaneous endoscopic gastrostomy complication rates in children: still a safe procedure. Surgery. 2012 Oct; 152(4):714-9; discussion 719-21. View Abstract

  53. The jury is still out: changes in gastroschisis management over the last decade are associated with both benefits and shortcomings. J Pediatr Surg. 2012 Jan; 47(1):119-24. View Abstract

  54. TGF-a equalizes age disparities in stem cell-mediated cardioprotection. J Surg Res. 2012 Aug; 176(2):386-94. View Abstract

  55. Pretreating mesenchymal stem cells with interleukin-1ß and transforming growth factor-ß synergistically increases vascular endothelial growth factor production and improves mesenchymal stem cell-mediated myocardial protection after acute ischemia. Surgery. 2012 Mar; 151(3):353-63. View Abstract

  56. Predictive value of response to steroid therapy on response to splenectomy in children with immune thrombocytopenic purpura. Surgery. 2011 Oct; 150(4):643-8. View Abstract

  57. Transforming growth factor-a enhances stem cell-mediated postischemic myocardial protection. Ann Thorac Surg. 2011 Nov; 92(5):1719-25. View Abstract

  58. Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia. Shock. 2011 Sep; 36(3):235-41. View Abstract

  59. Pretreatment with intracoronary mimosine improves postischemic myocardial functional recovery. Surgery. 2011 Aug; 150(2):191-6. View Abstract

  60. Systemic pretreatment with dimethyloxalylglycine increases myocardial HIF-1a and VEGF production and improves functional recovery after acute ischemia/reperfusion. Surgery. 2011 Aug; 150(2):278-83. View Abstract

  61. Transforming growth factor-alpha does not protect myocardium during acute ischemia/reperfusion. Surgery. 2011 Aug; 150(2):339-46. View Abstract

  62. Interleukin-10 protects the ischemic heart from reperfusion injury via the STAT3 pathway. Surgery. 2011 Aug; 150(2):231-9. View Abstract

  63. Intracoronary mesenchymal stem cells promote postischemic myocardial functional recovery, decrease inflammation, and reduce apoptosis via a signal transducer and activator of transcription 3 mechanism. J Am Coll Surg. 2011 Aug; 213(2):253-60. View Abstract

  64. IL-6 and TGF-a costimulate mesenchymal stem cell vascular endothelial growth factor production by ERK-, JNK-, and PI3K-mediated mechanisms. Shock. 2011 May; 35(5):512-6. View Abstract

  65. Female stem cells are superior to males in preserving myocardial function following endotoxemia. Am J Physiol Regul Integr Comp Physiol. 2011 Jun; 300(6):R1506-14. View Abstract

  66. TLR4 inhibits mesenchymal stem cell (MSC) STAT3 activation and thereby exerts deleterious effects on MSC-mediated cardioprotection. PLoS One. 2010 Dec 03; 5(12):e14206. View Abstract

  67. Surgical treatment of atrial fibrillation: the time is now. Ann Thorac Surg. 2010 Dec; 90(6):2079-86. View Abstract

  68. Toll-like receptor signaling pathways and the evidence linking toll-like receptor signaling to cardiac ischemia/reperfusion injury. Shock. 2010 Dec; 34(6):548-57. View Abstract

  69. The phosphoinositide-3 kinase survival signaling mechanism in sepsis. Shock. 2010 Nov; 34(5):442-9. View Abstract

  70. Ablation of TNF-alpha receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia. Shock. 2010 Sep; 34(3):236-42. View Abstract

  71. Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury. Surgery. 2011 Mar; 149(3):329-35. View Abstract

  72. The immunomodulatory properties of mesenchymal stem cells: implications for surgical disease. J Surg Res. 2011 May 01; 167(1):78-86. View Abstract

  73. Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery. 2010 Aug; 148(2):436-43. View Abstract

  74. Mesenchymal stem cells attenuate myocardial functional depression and reduce systemic and myocardial inflammation during endotoxemia. Surgery. 2010 Aug; 148(2):444-52. View Abstract

  75. Pericardial effusion and cardiac tamponade associated with central venous catheters in children: an uncommon but serious and treatable condition. J Pediatr Surg. 2010 Aug; 45(8):1687-92. View Abstract

  76. Optimizing stem cell function for the treatment of ischemic heart disease. J Surg Res. 2011 Mar; 166(1):138-45. View Abstract

  77. TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia. Shock. 2010 Jun; 33(6):602-7. View Abstract

  78. Postinfarct intramyocardial injection of mesenchymal stem cells pretreated with TGF-alpha improves acute myocardial function. Am J Physiol Regul Integr Comp Physiol. 2010 Jul; 299(1):R371-8. View Abstract

  79. Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome. Pediatr Nephrol. 2010 Sep; 25(9):1693-8. View Abstract

  80. Gender dimorphisms in progenitor and stem cell function in cardiovascular disease. J Cardiovasc Transl Res. 2010 Apr; 3(2):103-13. View Abstract

  81. Toll-like receptor 2 mediates mesenchymal stem cell-associated myocardial recovery and VEGF production following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2010 May; 298(5):H1529-36. View Abstract

  82. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock. 2010 Jan; 33(1):24-30. View Abstract

  83. Cell-based therapy for ischemic heart disease: a clinical update. Ann Thorac Surg. 2009 Nov; 88(5):1714-22. View Abstract

  84. What's new in Shock, October 2009? Shock. 2009 Oct; 32(4):345-7. View Abstract

  85. Proinflammatory cytokine effects on mesenchymal stem cell therapy for the ischemic heart. Ann Thorac Surg. 2009 Sep; 88(3):1036-43. View Abstract

  86. MEK, p38, and PI-3K mediate cross talk between EGFR and TNFR in enhancing hepatocyte growth factor production from human mesenchymal stem cells. Am J Physiol Cell Physiol. 2009 Nov; 297(5):C1284-93. View Abstract

  87. Proinflammatory stem cell signaling in cardiac ischemia. Antioxid Redox Signal. 2009 Aug; 11(8):1883-96. View Abstract

  88. Acute postischemic treatment with estrogen receptor-alpha agonist or estrogen receptor-beta agonist improves myocardial recovery. Surgery. 2009 Aug; 146(2):145-54. View Abstract

  89. Mesenchymal stem cells enhance the viability and proliferation of human fetal intestinal epithelial cells following hypoxic injury via paracrine mechanisms. Surgery. 2009 Aug; 146(2):190-7. View Abstract

  90. Animal models of myocardial and vascular injury. J Surg Res. 2010 Aug; 162(2):239-49. View Abstract

  91. Signal transducer and activator of transcription 3-stimulated hypoxia inducible factor-1alpha mediates estrogen receptor-alpha-induced mesenchymal stem cell vascular endothelial growth factor production. J Thorac Cardiovasc Surg. 2009 Jul; 138(1):163-71, 171.e1. View Abstract

  92. Stem cells in sepsis. Ann Surg. 2009 Jul; 250(1):19-27. View Abstract

  93. MEK mediates the novel cross talk between TNFR2 and TGF-EGFR in enhancing vascular endothelial growth factor (VEGF) secretion from human mesenchymal stem cells. Surgery. 2009 Aug; 146(2):198-205. View Abstract

  94. Both endogenous and exogenous testosterone decrease myocardial STAT3 activation and SOCS3 expression after acute ischemia and reperfusion. Surgery. 2009 Aug; 146(2):138-44. View Abstract

  95. High glucose concentration in cell culture medium does not acutely affect human mesenchymal stem cell growth factor production or proliferation. Am J Physiol Regul Integr Comp Physiol. 2009 Jun; 296(6):R1735-43. View Abstract

  96. Role of tumor necrosis factor receptor 1 in sex differences of stem cell mediated cardioprotection. Ann Thorac Surg. 2009 Mar; 87(3):812-9. View Abstract

  97. Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. Am J Physiol Regul Integr Comp Physiol. 2009 Apr; 296(4):R972-8. View Abstract

  98. Exogenous estrogen rapidly attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction. Shock. 2008 Dec; 30(6):660-7. View Abstract

  99. Nitric oxide suppresses the secretion of vascular endothelial growth factor and hepatocyte growth factor from human mesenchymal stem cells. Shock. 2008 Nov; 30(5):527-31. View Abstract

  100. Proestrus female rats are more resistant to right ventricular pressure overload. Shock. 2008 Sep; 30(3):318-23. View Abstract

  101. Spontaneous duodenal hematoma: a rare cause of upper gastrointestinal tract obstruction. Arch Surg. 2008 Aug; 143(8):794-6. View Abstract

  102. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit Care Med. 2008 Jul; 36(7):2174-83. View Abstract

  103. Deleterious effects of endogenous and exogenous testosterone on mesenchymal stem cell VEGF production. Am J Physiol Regul Integr Comp Physiol. 2008 May; 294(5):R1498-503. View Abstract

  104. [Results of 25 years of kidney transplantation]. Ann Urol (Paris). 2000 Oct; 34(5):352-8. View Abstract

  105. Comparison between allogeneic and xenogeneic lymphocyte reactivity. Transplant Proc. 1996 Oct; 28(5):2915-6. View Abstract

  106. Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France. Nephron. 1995; 69(1):97. View Abstract

  107. [Etiologies of chronic polyarthritis in Lomé (Togo)]. Rev Rhum Ed Fr. 1994 Jan; 61(1):29-35. View Abstract

  108. Split tolerance in chimeric GVH mice. Transpl Int. 1994; 7 Suppl 1:S606-10. View Abstract

  109. Proteinuria selectivity index--prognostic value in lipoid nephrosis and related diseases. Nephron. 1993; 65(2):185-9. View Abstract

  110. [Cholelithiasis: therapeutic strategy. Report from an European concensus conference]. Gastroenterol Clin Biol. 1992; 16(3):251-4. View Abstract

  111. IgA antigliadin antibodies as a possible marker for IgA mesangial glomerulonephritis in adults with primary glomerulonephritis. N Engl J Med. 1989 May 11; 320(19):1283-4. View Abstract
BESbswy